Japan Study: Hybrid Insulin Pump Improves Blood Sugar But Frustrates Patients

A study from Japan offers a revealing look at what happens when people with Type 1 diabetes upgrade to a more advanced insulin pump — and the results carry an important lesson for American patients considering the same technology.

What Researchers Did

Scientists at the Department of Metabolism & Endocrinology at Juntendo University Graduate School of Medicine in Tokyo followed 50 Japanese adults with Type 1 diabetes for a full year. All participants switched from the MiniMed™ 640G insulin pump to the newer MiniMed™ 770G, which uses hybrid closed-loop (HCL) technology — sometimes called an "artificial pancreas" system. This technology automatically adjusts insulin delivery based on continuous glucose monitor (CGM) readings, reducing the burden of manual insulin decisions.

What They Found: The Good News

The blood sugar results were genuinely encouraging. At the start of the study, patients spent about 67.3% of their time in the target glucose range of 70–180 mg/dL — already a reasonable baseline. After switching to the 770G, that number improved significantly within just 8 weeks and stayed better through the entire 52-week study period.

For context, the American Diabetes Association (ADA) recommends that people with Type 1 diabetes aim for at least 70% time in range (70–180 mg/dL). The Japanese participants moved closer to — and in many cases surpassed — this benchmark after upgrading their pump.

Time spent below range (under 70 mg/dL, meaning low blood sugar) did tick up slightly at week 8, but importantly, it stayed below 4% throughout the study — within the safe threshold recommended by international consensus guidelines.

The Catch: More Finger Sticks, Less Satisfaction

Here is where the Japanese experience diverges from what many patients hope for. To keep the 770G running in its automatic "auto mode," patients needed to perform significantly more traditional finger-stick blood glucose checks than they had with the older 640G system. That extra burden had a measurable impact: treatment satisfaction scores dropped significantly over the course of the year, even though overall quality-of-life scores did not show a statistically significant change.

In plain terms: the pump was working better, but patients felt more tied down by it.

Why This Matters for US Patients

The MiniMed 770G is also available in the United States, making this Japanese research directly relevant to American patients and their care teams. A few key takeaways:

• Better numbers don't always mean a better experience. If your doctor recommends upgrading to an HCL pump, ask specifically about how many daily finger sticks the system requires to stay in auto mode.
• The 770G has since been followed by the MiniMed 780G in the US, which requires fewer manual glucose checks. If finger-stick burden is a concern, ask your endocrinologist whether a newer system might offer the same blood sugar benefits with less hassle.
• Real-world data from diverse populations matters. Clinical trials often show ideal outcomes; observational studies like this one, conducted in everyday clinical settings, reveal the full picture — including the frustrations.
• Quality of life is a valid medical outcome. This study validates what many patients already feel: that a treatment's impact on daily life is just as important as its impact on lab values.

The Bottom Line

Hybrid closed-loop insulin pump technology represents a genuine step forward for Type 1 diabetes management, and this Japanese study confirms it can meaningfully improve time in range. But the right pump is the one that balances effective glucose control with a manageable daily routine. Talk openly with your diabetes care team about both the clinical and lifestyle trade-offs before making a switch.

Source: Kogai, Sato, Yasuda. "Effects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus." Journal of Diabetes Investigation, 2025. PMID: 39513544. DOI: 10.1111/jdi.14350